Amneal Pharmaceuticals, Inc. AMRX
21.38 USD +0.10 (+0.47%)
At closeNov 10, 2026, 5:31 PM EST
21.38 0.00 0.00%
After hours · Nov 10, 5:31 PM ET
21.03 Day range 21.63
11.48 52-week range 21.51
- YTD
- +69.68%
- 1 year
- +86.24%
News
globenewswire.com Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers BRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been named a BioSpace 2027 Best Place to Work,…
benzinga.com Leerink Partners Maintains Outperform on Amneal Pharmaceuticals, Raises Price Target to $25 Leerink Partners analyst Daniel Clark maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform and raises the price target from $23 to $25.
benzinga.com JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25 JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $24 to $25.
zacks.com AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised Amneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.
seekingalpha.com Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
marketbeat.com What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call Amneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an…
zacks.com Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.17 per share a year ago.
benzinga.com Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 Est; Raises FY2026 Sales Guidance from $3.100B-$3.200B to $3.150B-$3.250B vs $3.159B Est Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 analyst estimate. Raises FY2026 sales outlook from $3.100 billion-$3.200 billion to $3.150…
benzinga.com Amneal Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.23 Estimate, Sales $862.684M Beat $816.058M Estimate Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.23 by 13.04 percent. This is a 52.94 percent increase over earnings…
globenewswire.com Amneal Reports Third Quarter 2026 Financial Results – Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full…
zacks.com Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
zacks.com Implied Volatility Surging for Amneal Pharmaceuticals Stock Options Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
defenseworld.net 30,437 Shares of Amneal Pharmaceuticals, Inc. $AMRX Bought by Gibbs Wealth Management Gibbs Wealth Management bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) during the third quarter, according to the company in its most recent 13F filing with the…
zacks.com Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
benzinga.com JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24 JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.
defenseworld.net Head-To-Head Contrast: Neurocrine Biosciences (NASDAQ:NBIX) vs. Amneal Pharmaceuticals (NASDAQ:AMRX) Amneal Pharmaceuticals (NASDAQ: AMRX - Get Free Report) and Neurocrine Biosciences (NASDAQ: NBIX - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
fool.com Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
globenewswire.com Amneal to Report Third Quarter 2026 Results on November 3, 2026 BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on…
gurufocus.com A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- GF Value $8.19 vs Price $20.50 On September 28, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 3.7% to $20.50, reflecting strong price performance especially in the context of its 52-wee- benzinga.com Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27 Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.
globenewswire.com Amneal Announces FDA Approval and Launch of Lanreotide Injection - Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
zacks.com Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains? Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the…
benzinga.com Salesforce To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday Wall Street analysts made mixed price-target changes for LYFT, AMRX, JBHT, CRM, APPF, FLNC and CRWD.- benzinga.com Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20 Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.
gurufocus.com Amneal Pharmaceuticals Inc (AMRX) Stock Down 3.3% but Still Overvalued -- GF Score: 59/100 On September 15, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 3.3% to $16.65. This decline comes amid a 52-week trading range of $9.49 to $19.26, indicat
benzinga.com Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23 Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.- benzinga.com Amneal Pharmaceuticals Files Prospectus Related To The Offer And Sale Of Up To 28,942,098 Shares of Class A Common Stock By Selling Stockholders https://www.sec.gov/Archives/edgar/data/1723128/000114036126035617/ny20081412x1_s3asr.htm
zacks.com 5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
benzinga.com JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.- benzinga.com UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25 UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
benzinga.com Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050B-$3.150B to $3.100B-$3.200B vs $3.103B Est Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100…
benzinga.com Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.22 by 36.36 percent. This is a 20 percent increase over earnings of…
benzinga.com Two Years to Build or Pay 200% — Which US Pharma Stocks Win? Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.- benzinga.com Amneal Pharma Secures FDA Approval For Additional Strengths And Vial Presentations Of Iohexol Injection; Co. Plans To Launch These Products In Q3 Of 2026 Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolioPortfolio now…
- benzinga.com UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23 UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $19 to $23.
benzinga.com Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.
benzinga.com FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose
benzinga.com Top 3 Health Care Stocks That May Collapse This Quarter 3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, but positive price action for TGTX.
benzinga.com Earnings Scheduled For May 1, 2026 
benzinga.com Why Is Amneal Pharmaceuticals Stock Gaining Today? Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.- benzinga.com FDA Takes Step Forward on Testosterone Therapy for Men https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
- benzinga.com Earnings Scheduled For February 27, 2026
benzinga.com Earnings Scheduled For October 30, 2025 
benzinga.com Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com NY State Attorney General Letetia James Posts On X "My office and a coalition of AGs secured $720 million from eight pharmaceutical companies for their roles in fueling the opioid epidemic across our nation. We've now secured over $3 billion for New York that will be used to help prevent future devastation from opioids." https://x.com/NewYorkStateAG/status/1943364781936607687
benzinga.com Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.